- Home
- PWR vs TAK Comparison
PWR vs TAK Comparison
Compare PWR & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWR
- TAK
- Stock Information
- Founded
- PWR 1997
- TAK 1781
- Country
- PWR United States
- TAK Japan
- Employees
- PWR N/A
- TAK N/A
- Industry
- PWR Engineering & Construction
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- PWR Industrials
- TAK Health Care
- Exchange
- PWR Nasdaq
- TAK Nasdaq
- Market Cap
- PWR 56.7B
- TAK 47.3B
- IPO Year
- PWR 1998
- TAK N/A
- Fundamental
- Price
- PWR $389.52
- TAK $15.15
- Analyst Decision
- PWR Buy
- TAK
- Analyst Count
- PWR 22
- TAK 0
- Target Price
- PWR $391.16
- TAK N/A
- AVG Volume (30 Days)
- PWR 869.1K
- TAK 3.1M
- Earning Date
- PWR 10-30-2025
- TAK 10-30-2025
- Dividend Yield
- PWR 0.10%
- TAK 3.54%
- EPS Growth
- PWR 21.63
- TAK N/A
- EPS
- PWR 6.44
- TAK 0.59
- Revenue
- PWR $26,052,930,000.00
- TAK $31,053,301,865.00
- Revenue This Year
- PWR $18.05
- TAK $0.40
- Revenue Next Year
- PWR $12.09
- TAK $0.83
- P/E Ratio
- PWR $60.48
- TAK $25.94
- Revenue Growth
- PWR 18.26
- TAK 1.52
- 52 Week Low
- PWR $227.08
- TAK $12.80
- 52 Week High
- PWR $424.94
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- PWR 56.98
- TAK 53.11
- Support Level
- PWR $370.27
- TAK $14.87
- Resistance Level
- PWR $400.87
- TAK $15.38
- Average True Range (ATR)
- PWR 8.20
- TAK 0.18
- MACD
- PWR 1.61
- TAK -0.01
- Stochastic Oscillator
- PWR 70.01
- TAK 40.66
About PWR Quanta Services Inc.
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two segments: electric infrastructure and underground utility and infrastructure.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.